✦ LIBER ✦

Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer

✍ Scribed by Karen Reckamp; Barbara Gitlitz; Lin-Chi Chen; Ravi Patel; Ginger Milne; Mary Syto; Deborah Jezior; Sara Zaknoen

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 181 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25473

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II study of weekly high-dose e

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

✍ Daniel T. Milton; Christopher G. Azzoli; Robert T. Heelan; Ennapadam Venkatraman 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

Toxicity report of a phase 1/2 dose-esca

Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy

✍ Samuel Bral; Michaël Duchateau; Harijati Versmessen; Douwe Verdries; Benedikt En 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

A phase I-II study of docetaxel-ifosfami

A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer

✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n

Phase II study of pemetrexed in combinat

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

✍ Ralph G. Zinner; Frank V. Fossella; Gregory W. Gladish; Bonnie S. Glisson; Georg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

A phase 2 study of cetuximab in combinat

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

✍ Edward S. Kim; Ann M. Mauer; William N. William Jr; Hai T. Tran; Diane Liu; Jack 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

Phase 1 and pharmacokinetic study of eve

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer

✍ Suresh S. Ramalingam; R. Donald Harvey; Nabil Saba; Taofeek K. Owonikoko; John K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views